- Home
- Medicines
- Cardio-Metabolic
- Dermatology
- Haematology
- Neuroscience
- Oncology
- KISQALI®▼ (ribociclib)
- PIQRAY®▼ (alpelisib)
- TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
- Treatment of BRAF-Positive Metastatic Melanoma
- Adjuvant Treatment of Stage III BRAF-Positive Melanoma
- Management of patients with BRAF positive melanoma
- Resources
- Supporting Patients on Their TAFINLAR + MEKINIST Journey
- Supporting Patients Who Experience Side Effects on TAFINLAR + MEKINIST
- Brochure: Your Guide to Managing Pyrexia
- Video: Keeping Stage III BRAF V600-Positive Patients Relapse Free
- Video: Professor Caroline Robert discusses the landmark 5-year data with Tafinlar + Mekinist
- Video: Dr Paul Nathan discusses the COMBI-AD trial
- SANDOSTATIN LAR (octreotide acetate)
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- XOLAIR® (omalizumab)
- ATECTURA® BREEZHALER® (indacaterol acetate/mometasone furoate inhalation powder)
- ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)
- Rheumatology
- Therapy Areas
- Cardio-Metabolic
- Dermatology
- Haematology
- About SCD
- Acute myeloid leukaemia (AML)
- Chronic myeloid leukaemia (CML)
- Immune thrombocytopenia
- Myelodysplastic syndromes
- Myelofibrosis
- Thalassaemia
- Neuroscience
- Oncology
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- Rheumatology
- Events and Webinars
- Cardio-Metabolic
- Dermatology
- Haematology
- Neuroscience
- Oncology
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- Rheumatology
- Programmes
- Resources and Training
- Cardio-Metabolic
- Dermatology
- Product resources and training
- Cosentyx® (secukinumab) HCP resources for patients
- The You First programme
- XOLAIR® (omalizumab) Resources
- Therapy area resources and training
- Product resources and training
- Haematology
- Neuroscience
- Oncology
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- Rheumatology
×
Ask Speakers
×
Medical Information Request
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com